The scale and seniority of this insider buying cluster is a strong signal that management sees material upside from current levels. Traders should watch for near-term clinical data catalysts (ivonescimab trial readouts). However, historical insider cluster calls on SMMT have been negative at T+20, so size positions accordingly and consider a trailing stop.
Price Chart
Executive Summary
Both co-CEOs of Summit Therapeutics (SMMT) each purchased 3.81M shares open-market on June 12, 2026, at $13.12, aggregating ~$100M. This represents ~0.98% of market cap, one of the largest insider buying clusters by dollar value relative to size in the sector. The unanimous C-suite buying signals extreme management conviction, though prior insider cluster predictions on SMMT have underperformed.
Key Financial Metrics
Key Facts
- Co-CEOs Robert W. Duggan and Mahkam Zanganeh each purchased 3,810,000 shares on June 12, 2026.
- Total insider buying value: ~$99.97M at $13.12/share.
- Total value equals ~0.98% of SMMT's $10.2B market cap.
- Both purchases were open-market (code P) — not grants or options exercises.
- The cluster occurred within a 7-day window with no other insider trades.
Financial Impact
~$100M in insider open-market buying, ~0.98% of market cap.
Risk Factors
- Biotech clinical trial risk (ivonescimab data may disappoint).
- Prior insider cluster reports on SMMT showed negative T+20 returns (avg -19%), suggesting this signal may be less reliable for this ticker.
- The stock already has a $10.2B market cap — limited upside if market has already priced in optimism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SMMT-1781289346843 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access